News Articles

PierianDx Closes up to $47.5 Million of Growth Capital ST. LOUIS -Wednesday 3 November 2021

(BUSINESS WIRE)-- PierianDx, the global leader in clinical genomics knowledge, announced that it closed on $30 million of new growth capital including equity financing and a term loan facility, which includes access to additional tranches for up to $17.5 million by 2022 and 2023, subject to...

PierianDx Announces the Appointment of Lindsay Mateo as Chief Business Officer -Wednesday 3 March 2021

(BUSINESS WIRE)-- PierianDx, the global leader in clinical genomics knowledge, today announced the appointment of Lindsay Mateo as Chief Business Officer, effective immediately. In her new role, Ms. Mateo will reinforce the company’s position as the leading provider of clinical genomics...

PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets -Wednesday 2 December 2020

(BUSINESS WIRE) -- PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina® Focus Panel, AmpliSeq™ for Illumina® Myeloid Panel and the...

PierianDx and Bench International Announce the Appointment of Mark McDonough as New CEO -Wednesday 18 November 2020

(BUSINESS WIRE)-- PierianDx, the leading clinical genomics informatics company, and Bench International, a leading global executive search firm, jointly announce the appointment of Mark McDonough as Chief Executive Officer (CEO) and member of the Board of Directors of PierianDx, effective...

PierianDx and Pillar Biosciences Announce Partnership to Support Precision Cancer Care -Thursday 15 October 2020  

(BUSINESS WIRE)-- PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx clinical genomic report in...